Funko Inc
Change company Symbol lookup
Select an option...
FNKO Funko Inc
OIG Orbital Infrastructure Group Inc
FPI Farmland Partners Inc
HNST Honest Company Inc
ONTF ON24 Inc
ATAI ATAI Life Sciences NV
FTS Fortis Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
NEGG Newegg Commerce Inc
Go

Consumer Discretionary : Distributors | Small Cap Blend
Company profile

Funko, Inc. is a pop culture consumer products company. The Company is engaged in selling a broad range of pop culture consumer products, featuring characters from a range of media and entertainment content, including movies, TV shows, video games, music and sports. Its products fall under figures and other product categories. Its figures category includes figures that celebrate pop culture icons in the form of stylized vinyl, blind-packed miniatures and action figures. It includes brands, such as Pop!, Mystery Minis, and Funko Soda. Its other category is comprised of stylized fashion accessories including bags, backpacks and wallets; apparel; board games; plush products; accessories including keychains, pens and pins; apparel including t-shirts and hats; homewares including drinkware and other home accessories; non-fungible tokens (NFTs) and other. It sells its products through a network of retail customers, including specialty retailers, mass-market retailers, and e-commerce sites.

Postmarket

Last Trade
Delayed
$20.30
0.46 (2.32%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$19.84
Day's Change
-0.13 (-0.65%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
20.79
Day's Low
19.71
Volume
(Average)
Volume:
681,225

10-day average volume:
726,630
681,225

Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals

8:24 am ET July 29, 2022 (PR Newswire) Print

Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections for birth control coverage under the Affordable Care Act (ACA).

https://mma.prnewswire.com/media/780907/Evofem_Biosciences_Logo.jpg

"Yesterday, the United States took a critical step forward in protecting the right to contraception. The Departments of Labor, Health and Human Services, and Treasury released guidance clarifying that group health plans and insurers must cover contraceptives, including emergency contraceptives, at no cost to individuals," said Saundra Pelletier, CEO of Evofem Biosciences. "It is truly gratifying that our government is supporting those of us across the country -- in the private sector and in advocacy organizations -- who are on the front lines of producing contraception options and having them fully covered in healthcare plans."

Under the ACA, most private health plans are required to provide birth control and family planning counseling at no additional cost.

Evofem's market access team intends to renew discussions with insurers and pharmacy benefit managers (PBMs) that are not yet compliant with these guidelines to ensure they cover Phexxi(R) (lactic acid, citric acid and potassium bitartrate) at no cost to individuals.

About Evofem Biosciences Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi(R) (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data this fall from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications - prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.

Phexxi(R) is a registered trademark of Evofem Biosciences, Inc.

Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including, without limitation, evaluations and judgments regarding Evofem, its products, its product candidates and their development, demand for Evofem's products and product candidates and Affordable Care Act. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward- looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022 and its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Investor Relations Contact Media Contact
Amy Raskopf                media@evofem.com
araskopf@evofem.com
Mobile: (917) 673-5775

https://c212.net/c/img/favicon.png?sn=LA30939&sd=2022-07-29

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-commends-tri-agencies-for-clarifying-that-contraceptives-must-be-covered-at-no-cost-to-individuals-301595942.html

SOURCE Evofem Biosciences, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=LA30939&Transmission_Id=202207290824PR_NEWS_USPR_____LA30939&DateId=20220729

comtex tracking

COMTEX_411228805/1005/2022-07-29T08:24:07

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.